MedTrace Logo

MR/PET in the Evaluation of Patients With Esophageal Cancer

NCT02547610 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2017-05-16

No results posted yet for this study

Summary

In this prospective study, we will recruit newly diagnosed esophageal cancer patients and perform MR/PET before and after chemoradiation therapy. In MR, new image sequences will be added to the conventional sequences, such as high resolution image, DWI, DCE, cine imaging.

Conditions

  • Esophageal Cancer

Interventions

DEVICE

The imaging biomarkers determined by MR-PET

Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Tiffany Ting-Fang Shih, M.D. · Department of Medical Imaging, National Taiwan University Hospital.

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-12-31
Completion
2018-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02547610 on ClinicalTrials.gov